azaserine has been researched along with Carcinoma--Hepatocellular* in 5 studies
1 review(s) available for azaserine and Carcinoma--Hepatocellular
| Article | Year |
|---|---|
Some antineoplastic antibiotics.
Topics: Adenocarcinoma; Amino Sugars; Animals; Antibiotics, Antineoplastic; Azaserine; Benzazepines; Bleomycin; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Cricetinae; Dactinomycin; Daunorubicin; DNA; Dogs; Glycosides; Haplorhini; Humans; Leukemia L1210; Liver Neoplasms; Lymphoma; Mice; Mitomycins; Naphthacenes; Plicamycin; Pyrroles; Rats; RNA; Sarcoma 180; Streptonigrin; Streptozocin | 1972 |
4 other study(ies) available for azaserine and Carcinoma--Hepatocellular
| Article | Year |
|---|---|
Regulatory role of hexosamine biosynthetic pathway on hepatic cancer stem cell marker CD133 under low glucose conditions.
Cancer was hypothesized to be driven by cancer stem cells (CSCs), but the metabolic determinants of CSC-like phenotype still remain elusive. Here, we present that hexosamine biosynthetic pathway (HBP) at least in part rescues cancer cell fate with inactivation of glycolysis. Firstly, metabolomic analysis profiled cellular metabolome in CSCs of hepatocellular carcinoma using CD133 cell-surface marker. The metabolic signatures of CD133-positive subpopulation compared to CD133-negative cells highlighted HBP as one of the distinct metabolic pathways, prompting us to uncover the role of HBP in maintenance of CSC-like phenotype. To address this, CSC-like phenotypes and cell survival were investigated in cancer cells under low glucose conditions. As a result, HBP inhibitor azaserine reduced CD133-positive subpopulation and CD133 expression under high glucose condition. Furthermore, treatment of N-Acetylglucosamine in part restores CD133-positive subpopulation when either 2.5 mM glucose in culture media or glycolytic inhibitor 2-deoxy-D-glucose in HCC cell lines was applied, enhancing CD133 expression as well as promoting cancer cell survival. Together, HBP might be a key metabolic determinant in the functions of hepatic CSC marker CD133. Topics: AC133 Antigen; Azaserine; Biomarkers; Biosynthetic Pathways; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Glucose; Glycolysis; Hexosamines; Humans; Liver Neoplasms; Metabolomics; Neoplastic Stem Cells; Phenotype | 2016 |
Azaserine carcinogenesis: organ susceptibility change in rats fed a diet devoid of choline.
Topics: Animals; Azaserine; Body Weight; Carcinogens; Carcinoma, Hepatocellular; Choline; Diet; Liver; Liver Neoplasms; Male; Neoplasms, Experimental; Organ Size; Pancreas; Pancreatic Neoplasms; Rats | 1978 |
GROWTH INHIBITION OF A SPECTRUM OF TRANSPLANTED MOUSE TUMORS BY COMBINATIONS OF INHIBITORS OF NUCLEIC ACID BIOSYNTHESIS AND ALKYLATING AGENTS.
Topics: Alkylating Agents; Animals; Antineoplastic Agents; Azaguanine; Azaserine; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; DNA; DNA, Neoplasm; Fluorouracil; Idoxuridine; Liver Neoplasms; Lymphoma; Lymphoma, Non-Hodgkin; Mercaptopurine; Mice; Neoplasms, Experimental; Nitrogen Mustard Compounds; Nucleosides; Nucleotides; Purines; Research; RNA; RNA, Neoplasm; Sarcoma 180; Thioguanine; Uracil Mustard | 1963 |
Utilization of preformed purines by sarcoma 180 or hepatoma 134 cells treated with 6-chloropurine or a combination of 6-chloropurine and azaserine.
Topics: Animals; Antineoplastic Agents; Azaserine; Carcinoma, Hepatocellular; Liver Neoplasms; Neoplasms; Purines; Sarcoma; Sarcoma 180 | 1960 |